Trial Profile

A Phase II, Open Label, Single Arm Study of Neoadjuvant Pembrolizumab and Lenvatinib for Patients With Resectable Stage III Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Skin cancer
Focus Therapeutic Use
Acronyms Neo PeLe

Most Recent Events

04 Jun 2024 Results assessing Analysis of tumor microenvironment (TME) correlated to pathological response presented at the 60th Annual Meeting of the American Society of Clinical Oncology
12 Feb 2024 Status changed from recruiting to active, no longer recruiting.
15 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com